Literature DB >> 6508981

Haemodynamic dose-response effects of i.v. nicardipine in coronary artery disease.

B Silke, S P Verma, G I Nelson, M Hussain, S H Taylor.   

Abstract

The haemodynamic dose-response effects of the slow channel blocking agent nicardipine were evaluated in 10 male patients with angiographically confirmed coronary artery disease. At rest, following a similar control saline period, four doses of the drug (log cumulative dosage: 1.25, 2.5, 5.0 and 10.0 mg) were administered by i.v. infusion over a total duration of 40 min; haemodynamic variables were recorded in the 3-5 min following each 5 min infusion. During steady-state exercise the haemodynamic effects of the drug were evaluated by comparison of a control exercise period with observations made at the same workload (200-500 kpm) following the maximum cumulative dose (10 mg). Following the four i.v. infusions, the plasma nicardipine level increased log-linearly with the infused dose (r = 0.68). Compared with control measurements at rest after saline, these plasma concentrations (35 +/- 8 to 141 +/- 24 micrograms/l) resulted in a linear decrease in systemic blood pressure and vascular resistance with significant increase in cardiac index (maximum delta CI + 1.6 l min(-1) m(-2); P less than 0.01), stroke index (maximum delta SI + 11 ml/m2; P less than 0.01) and in pulmonary artery occluded pressure (maximum delta PAOP + 2 mm Hg; P less than 0.01). There was a significant increase in heart rate; the stroke work index was unchanged. During upright bicycle exercise the reduction in systemic blood pressure was accompanied by an increased exercise cardiac output without change in stroke index. The exercise pulmonary artery occluded pressure was unchanged compared with control observations, the stroke work index fell significantly (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508981      PMCID: PMC1463544          DOI: 10.1111/j.1365-2125.1984.tb02534.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  The effect of nifedipine on the sinus and atrioventricular node of the dog heart after beta-adrenergic receptor blockade.

Authors:  J P Amlie; K Landmark
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-04

Review 2.  Measurement of the cardiac output in man.

Authors:  S H Taylor
Journal:  Proc R Soc Med       Date:  1966

Review 3.  The hemodynamic effects of calcium channel blocking agents: a brief review.

Authors:  J Kieval; R J Myerburg
Journal:  Angiology       Date:  1982-08       Impact factor: 3.619

Review 4.  Role of calcium antagonists in cardiovascular therapy.

Authors:  H Dargie; E Rowland; D Krikler
Journal:  Br Heart J       Date:  1981-07

5.  The effect on left ventricular performance of nifedipine and metoprolol singly and together in exercise-induced angina pectoris.

Authors:  G I Nelson; B Silke; R C Ahuja; M Hussain; D Forsyth; S H Taylor
Journal:  Eur Heart J       Date:  1984-01       Impact factor: 29.983

6.  Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischemia-induced left ventricular dysfunction.

Authors:  M Pfisterer; J Müller-Brand; F Burkart
Journal:  Am J Cardiol       Date:  1982-04-01       Impact factor: 2.778

Review 7.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

8.  Antianginal efficiency of nifedipine with and without a beta-blocker, studied with exercise test. A double-blind, randomized subacute study.

Authors:  L G Ekelund; L Orö
Journal:  Clin Cardiol       Date:  1979-06       Impact factor: 2.882

9.  The combination of nifedipine and propranolol in the management of patients with angina pectoris.

Authors:  A C Tweddel; J M Beattie; R G Murray; I Hutton
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

10.  Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination.

Authors:  P Lynch; H Dargie; S Krikler; D Krikler
Journal:  Br Med J       Date:  1980-07-19
View more
  10 in total

1.  Cardiovascular interaction between sevoflurane and nicardipine in open chest dogs.

Authors:  N Iwatsuki; A Kaise; Y Koga; H Ishii
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

2.  A haemodynamic and radionuclide assessment of diltiazem in coronary heart disease.

Authors:  B Silke; S K Sharma; S P Verma; K A Midtbo; G Reynolds; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

3.  Effects and interaction of nicardipine and volatile anesthetics in the rat heart-lung preparation.

Authors:  Satoshi Kashimoto; Toshihiro Nakamura; Masaki Kume; Akihiko Nonaka; Teruo Kumazawa
Journal:  J Anesth       Date:  1994-03       Impact factor: 2.078

4.  Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.

Authors:  B Silke; S P Verma; A V Zezulka; S Sharma; G Reynolds; N C Jackson; S Guy; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

5.  Hemodynamic interactions of a new beta blocker, celiprolol, with nifedipine in angina pectoris.

Authors:  B Silke; S P Verma; S Guy
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

6.  Effects of nicardipine on cardiac volume at rest and during exercise-induced angina.

Authors:  B Silke; S P Verma; M A Frais; M Hafizullah; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine.

Authors:  M Bellet; P Sassano; T Guyenne; P Corvol; J Menard
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 8.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

9.  Haemodynamic dose-response effects of intravenous nisoldipine in coronary artery disease.

Authors:  B Silke; M A Frais; P Muller; S P Verma; G Reynolds; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

10.  Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease.

Authors:  B Silke; D J Graham; S P Verma; G Reynolds; M A Frais; J R Finlayson; S H Taylor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.